With two of its prized gene therapies on clinical hold and another, Zynteglo, pulled from the market in Europe seven months ago after it was …
Unable to reach a consensus with authorities in Europe around fair gene therapy pricing, bluebird bio will “wind down” its operations there to focus on …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
